August 2026– date –
-
Antibiotics Reshape Gut Microbiome, Doubling Circulation Time and Tumor Accumulation of Nano-Chemotherapy, Improving Survival
University of Texas M. D. Anderson Cancer Center USA Overview Researchers at The University of Texas MD Anderson Cancer Center discovered that reshaping the gut microbiome with a short course of antibiotics can enhance the delivery of na... -
Insilico Medicine Advances AI-Designed Drug to Phase III for IPF, with 31 Candidates Beyond Preclinical Stage
Forbes USA Overview Generative biology, leveraging AI to design drug molecules, proteins, and DNA, is pushing AI-designed candidates into human trials. Insilico Medicine has a Phase III drug for idiopathic pulmonary fibrosis and 31 devel... -
Viral Vector CDMO Capacity Exceeds Clinical Demand: Catalent and Lonza Lead AAV Manufacturing Expansion
IntuitionLabs USA Overview An August 2026 analyst report reveals that viral vector manufacturing capacity, especially for AAV, has outpaced current clinical demand, offering gene therapy sponsors more options and competitive lead times. ... -
China’s AsymBio Secures $184M to Dramatically Expand Biologics CDMO Capacity, Bolstering ADC Production
PharmaSource China Overview AsymBio, a Chinese biologics CDMO, secured approximately $184 million (1.2397 billion Yuan) in financing to substantially expand its manufacturing capacity, R&D capabilities, GMP manufacturing lines, and h... -
LNP Design Innovations Enable Extrahepatic Nucleic Acid Delivery: Paving Way for Mucosal Administration Routes
MDPI Switzerland Overview Recent breakthroughs in lipid nanoparticle (LNP) design, driven by altered formulation composition and chemical modification of ionizable lipids, are enabling organ-selective nucleic acid delivery beyond the liv... -
Bioengineering Strategies Overcome Liver Tropism to Improve Cardiac Targeting of LNPs for Heart Disease Therapy
Arteriosclerosis, Thrombosis, and Vascular Biology - American Heart Association Journals USA Overview Despite promise in cardiovascular disease treatment, nanomedicines face challenges of insufficient cardiac targeting and poor retention... -
VERVE-101 Achieves 53-69% LDL-C Reduction in Lipid Disorder Trials, Accelerating LNP-Based Gene Editing Therapeutics
PMC (Part of MDPI) Switzerland Overview VERVE-101, an in vivo base editing therapy targeting PCSK9 via mRNA-LNP delivery, has progressed to clinical trials (NCT05398029) for lipid disorders, showing significant LDL-C reductions of 53% to... -
Nanotechnology Revolutionizes Cancer Treatment: EPR Effect Enables Tumor-Selective Drug Delivery and Reduced Toxicity
HCG Oncology India Overview Nanotechnology is revolutionizing cancer treatment by delivering therapeutic drug doses to tumors while minimizing collateral damage to healthy tissue. Nano-drugs, engineered within nanocarrier platforms like ... -
CDMOs Boost Sterile Fill-Finish and Prefilled Syringe Capacity by Over $1 Billion to Meet Biologics and GLP-1 Drug Demand
BioProcess International USA Overview Contract Manufacturing and Development Organizations (CMOs/CDMOs) are making multi-billion dollar investments, including PCI Pharma Services' global $1 billion expansion, to significantly increase st... -
Roche’s Cevostamab Achieves 42.1% ORR in Phase 1 for Relapsed/Refractory Multiple Myeloma
OncLive USA Overview Roche's investigational FcRH5 x CD3 bispecific antibody cevostamab (RG6160) demonstrated an overall response rate (ORR) of 42.1% across all dose levels (n=324) in a Phase 1 trial for relapsed/refractory multiple myel...
